Bicocca Open Archive

Logo unimib boa
CECCON, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.152
EU - Europa 1.642
AS - Asia 1.491
SA - Sud America 219
AF - Africa 39
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 6.547
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.069
SG - Singapore 579
CN - Cina 396
DE - Germania 339
IT - Italia 262
RU - Federazione Russa 226
HK - Hong Kong 219
IE - Irlanda 191
SE - Svezia 188
BR - Brasile 174
GB - Regno Unito 119
VN - Vietnam 114
UA - Ucraina 95
CA - Canada 68
FI - Finlandia 45
IN - India 41
AT - Austria 40
FR - Francia 40
JP - Giappone 25
PL - Polonia 24
AR - Argentina 23
TR - Turchia 23
ID - Indonesia 22
BE - Belgio 21
ZA - Sudafrica 20
BD - Bangladesh 18
DK - Danimarca 14
MX - Messico 12
KR - Corea 11
NL - Olanda 10
ES - Italia 9
IQ - Iraq 9
VE - Venezuela 7
LT - Lituania 6
IR - Iran 5
MA - Marocco 5
BG - Bulgaria 4
TN - Tunisia 4
CO - Colombia 3
EC - Ecuador 3
JO - Giordania 3
NP - Nepal 3
PE - Perù 3
PS - Palestinian Territory 3
PY - Paraguay 3
AZ - Azerbaigian 2
CL - Cile 2
DZ - Algeria 2
EU - Europa 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
MU - Mauritius 2
PK - Pakistan 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CH - Svizzera 1
EE - Estonia 1
EG - Egitto 1
HN - Honduras 1
KZ - Kazakistan 1
MD - Moldavia 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
RO - Romania 1
SC - Seychelles 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
UZ - Uzbekistan 1
YE - Yemen 1
Totale 6.547
Salva come PNG Salva come JPEG
Città #
Ann Arbor 502
Singapore 314
Ashburn 287
Hong Kong 219
Frankfurt am Main 218
Fairfield 207
Chandler 206
Woodbridge 206
Dublin 188
Houston 156
Milan 142
Wilmington 137
Dearborn 107
New York 96
Jacksonville 90
Seattle 89
Cambridge 74
Beijing 64
Santa Clara 63
Los Angeles 61
Princeton 53
Nanjing 47
Dallas 39
Ho Chi Minh City 39
Vienna 36
Munich 29
Hefei 28
Shanghai 25
Altamura 24
Lawrence 23
Nanchang 22
São Paulo 20
Brussels 19
Hanoi 18
Buffalo 17
Jakarta 17
Moscow 17
San Diego 17
Chicago 16
Montreal 16
Tokyo 16
Lachine 15
Turku 15
Warsaw 15
Boardman 14
Fremont 13
Brooklyn 12
Guangzhou 12
Göttingen 12
Helsinki 12
Johannesburg 12
Rio de Janeiro 12
Denver 11
Toronto 11
London 10
Norwalk 10
Orem 10
Phoenix 10
Poplar 10
Falls Church 9
Hangzhou 9
Lissone 9
Pune 9
Salt Lake City 9
Seoul 9
Andover 8
Chennai 8
Council Bluffs 8
Ottawa 8
Shenyang 8
Tianjin 8
Atlanta 7
Chengdu 7
Da Nang 7
Edmonton 7
Jiaxing 7
Lodz 7
Manchester 7
Taizhou 7
Düsseldorf 6
Hebei 6
Kunming 6
Nuremberg 6
Romola 6
Boston 5
Changsha 5
Haiphong 5
Jinan 5
Kent 5
Kiev 5
Kocaeli 5
Mexico City 5
Monza 5
San Francisco 5
Taku 5
The Dalles 5
Zhengzhou 5
Amsterdam 4
Ankara 4
Brasília 4
Totale 4.445
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 436
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 395
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 367
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 315
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 313
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 305
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 275
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 272
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 265
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 258
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 247
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 247
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 238
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth 232
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 217
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 210
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 201
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 196
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 194
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 181
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 180
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 170
Crizotinib-resistan NPM-ALK mutants confer differential sensitivity to unrelated alk inhibitors 164
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 162
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 161
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 160
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 146
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 139
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 118
Totale 6.764
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.915
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.915
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021375 0 0 0 0 0 76 50 59 40 59 32 59
2021/2022353 27 33 24 13 30 40 20 25 18 39 32 52
2022/2023849 83 244 88 88 60 114 8 58 52 20 19 15
2023/2024523 16 18 24 25 58 169 101 12 36 9 2 53
2024/20251.115 67 114 57 54 100 42 75 31 134 181 90 170
2025/20261.508 362 137 226 384 386 13 0 0 0 0 0 0
Totale 6.764